Latest Pharma Insights
US FDA Cites Private Labeler For Quality Violations
Private Label Skin Care Inc. has violated Current Good Manufacturing Practice regulations for pharmaceuticals, according to the agency.
HBW Insight - January 14, 2026
Private Label Skin Care Inc. has violated Current Good Manufacturing Practice regulations for pharmaceuticals, according to the agency.
HBW Insight - January 14, 2026
J.P. Morgan Notebook: Strategies For Business Development, FDA Change & Pricing
Execs from Merck and Italfarmico talk business development, while Takeda's Plump addresses regulatory uncertainty in the US and Ionis CEO Monia discusses pricing for Tryngolza, plus more news from day two of J.P. Morgan.
Scrip - January 14, 2026
Execs from Merck and Italfarmico talk business development, while Takeda's Plump addresses regulatory uncertainty in the US and Ionis CEO Monia discusses pricing for Tryngolza, plus more news from day two of J.P. Morgan.
Scrip - January 14, 2026
US OTC Drug Industry’s Input On PDUFA Reauthorization Emphasizes Switch NDA Output
In PDUFA reauthorization subgroup meetings, CHPA suggests expanding FDA’s special protocol assessment program to include OTC drug studies before FDA notes Congress has required it to provide switch-specific guidance before current PDUFA expires.
HBW Insight - January 14, 2026
In PDUFA reauthorization subgroup meetings, CHPA suggests expanding FDA’s special protocol assessment program to include OTC drug studies before FDA notes Congress has required it to provide switch-specific guidance before current PDUFA expires.
HBW Insight - January 14, 2026
J.P. Morgan Notebook: Strategies For Business Development, FDA Change & Pricing
Execs from Merck and Italfarmico talk business development, while Takeda's Plump addresses regulatory uncertainty in the US and Ionis CEO Monia discusses pricing for Tryngolza, plus more news from day two of J.P. Morgan.
Scrip - January 14, 2026
Execs from Merck and Italfarmico talk business development, while Takeda's Plump addresses regulatory uncertainty in the US and Ionis CEO Monia discusses pricing for Tryngolza, plus more news from day two of J.P. Morgan.
Scrip - January 14, 2026
Deals Shaping The Medtech And Diagnostics Industries, December 2025
An interactive look at medtech and diagnostics deals made during December 2025. Data courtesy of Biomedtracker.
Medtech Insight - January 13, 2026
An interactive look at medtech and diagnostics deals made during December 2025. Data courtesy of Biomedtracker.
Medtech Insight - January 13, 2026
Medtronic Pivots Back to Tuck-In M&A as Board, Balance Sheet And Pipeline Align
Medtronic CEO Geoffrey Martha said tuck-in deals for Medtronic would typically be in the low to mid-single-digit billions. While no timing or targets were disclosed, CFO Thierry Pieton said the company has the balance sheet strength to pursue acquisitions without changing its capital return strategy
Medtech Insight - January 13, 2026
Medtronic CEO Geoffrey Martha said tuck-in deals for Medtronic would typically be in the low to mid-single-digit billions. While no timing or targets were disclosed, CFO Thierry Pieton said the company has the balance sheet strength to pursue acquisitions without changing its capital return strategy
Medtech Insight - January 13, 2026
Medtech 2026: AI Shows Patient Care Potential, But Regulation Remains Tricky
AI in medtech offers exciting potential for improving patient care and operational efficiency, but faces significant regulatory challenges. Ensuring data quality and building trust among users are essential for successful AI integration in healthcare, our expert panel said.
Medtech Insight - January 13, 2026
AI in medtech offers exciting potential for improving patient care and operational efficiency, but faces significant regulatory challenges. Ensuring data quality and building trust among users are essential for successful AI integration in healthcare, our expert panel said.
Medtech Insight - January 13, 2026
Medtech 2026: Collaboration, Coverage Improvements Top Industry Wish Lists
Wishes for 2026 from our medtech experts focused on value-based care, faster reimbursements, and better collaboration. Key ideas included enhancing patient engagement, reducing waste, and aligning coverage policies to improve health outcomes and innovation.
Medtech Insight - January 13, 2026
Wishes for 2026 from our medtech experts focused on value-based care, faster reimbursements, and better collaboration. Key ideas included enhancing patient engagement, reducing waste, and aligning coverage policies to improve health outcomes and innovation.
Medtech Insight - January 13, 2026
Medtech 2026: Complexity, Bottlenecks And Cybersecurity Among Key Regulatory Concerns
As medtech moves toward 2026, experts highlight increased regulatory complexities, particularly around AI, cybersecurity, and device user fees. Urgent regulatory updates are needed to keep pace with rapid technology changes while ensuring patient safety and operational efficiency.
Medtech Insight - January 13, 2026
As medtech moves toward 2026, experts highlight increased regulatory complexities, particularly around AI, cybersecurity, and device user fees. Urgent regulatory updates are needed to keep pace with rapid technology changes while ensuring patient safety and operational efficiency.
Medtech Insight - January 13, 2026
Medtech 2026: Is Investor Confidence Back?
Our experts said investor confidence in medtech is recovering as we head into 2026. Expect larger, selective fundraising and heightened M&A activity, focusing on innovative firms in neurology, cardiovascular health, and AI-driven technologies. Companies with solid strategies are favored.
Medtech Insight - January 13, 2026
Our experts said investor confidence in medtech is recovering as we head into 2026. Expect larger, selective fundraising and heightened M&A activity, focusing on innovative firms in neurology, cardiovascular health, and AI-driven technologies. Companies with solid strategies are favored.
Medtech Insight - January 13, 2026
US FDA Cites Private Labeler For Quality Violations
Private Label Skin Care Inc. has violated Current Good Manufacturing Practice regulations for pharmaceuticals, according to the agency.
HBW Insight - January 14, 2026
Private Label Skin Care Inc. has violated Current Good Manufacturing Practice regulations for pharmaceuticals, according to the agency.
HBW Insight - January 14, 2026
US OTC Drug Industry’s Input On PDUFA Reauthorization Emphasizes Switch NDA Output
In PDUFA reauthorization subgroup meetings, CHPA suggests expanding FDA’s special protocol assessment program to include OTC drug studies before FDA notes Congress has required it to provide switch-specific guidance before current PDUFA expires.
HBW Insight - January 14, 2026
In PDUFA reauthorization subgroup meetings, CHPA suggests expanding FDA’s special protocol assessment program to include OTC drug studies before FDA notes Congress has required it to provide switch-specific guidance before current PDUFA expires.
HBW Insight - January 14, 2026
Adalvo Lines Up Semaglutide DCP Filing Ahead Of EU Exclusivity Expiry
The planned submission marks a key regulatory step toward potential day-one launches in Europe.
Generics Bulletin - January 13, 2026
The planned submission marks a key regulatory step toward potential day-one launches in Europe.
Generics Bulletin - January 13, 2026
Larkins Resurfaces As Par’s New Injectables Chief
A couple of months after leaving Hikma, former Custopharm CEO and Hikma injectables chief Bill Larkins has been named as the new president of Par Health’s injectables business.
Generics Bulletin - January 13, 2026
A couple of months after leaving Hikma, former Custopharm CEO and Hikma injectables chief Bill Larkins has been named as the new president of Par Health’s injectables business.
Generics Bulletin - January 13, 2026
All Change! Multiple Moves Shake Up US Ranibizumab Market
The US ranibizumab market has seen more than its fair share of ups and downs, with the latest developments vastly reducing biosimilar penetration and allowing Lucentis to recapture around 90% of the market. Generics Bulletin looks at the reasons why.
Generics Bulletin - January 13, 2026
The US ranibizumab market has seen more than its fair share of ups and downs, with the latest developments vastly reducing biosimilar penetration and allowing Lucentis to recapture around 90% of the market. Generics Bulletin looks at the reasons why.
Generics Bulletin - January 13, 2026
EIT Innovation Program Delivers A KIC-Start For EU Medtech Ventures
EIT Health has helped 3,000 start-ups and SMEs scale across Europe and supported over 120 innovations to launch. Inspired by the US MIT, the EIT Health program is on a mission to raise awareness of its value to healthtech innovators as it embarks on new methods of funding its own activities.
In Vivo - January 13, 2026
EIT Health has helped 3,000 start-ups and SMEs scale across Europe and supported over 120 innovations to launch. Inspired by the US MIT, the EIT Health program is on a mission to raise awareness of its value to healthtech innovators as it embarks on new methods of funding its own activities.
In Vivo - January 13, 2026